FDA Paper To Address Cross-Labeling For Combination Products
This article was originally published in The Gray Sheet
Executive Summary
FDA is developing a document to help clarify some thorny issues related to cross-labeling of combination products and plans to host a public meeting on the issue soon, industry sources say
You may also be interested in...
Cross-Labeling Challenges Lack Easy Fix; Data Exclusivity Incentive Floated
Data exclusivity extensions have been proposed as an incentive to encourage drug firms to amend product labeling in deference to related devices, but FDA and industry reps warn of complications inherent in this strategy
Executives On The Move: Changes At The Top At Enzolytics, Dyne Therapeutics And Seres Therapeutics
Recent moves in the industry include new chief financial officers at LENZ Therapeutics and Botanix Pharmaceuticals, plus new chief medical officers at Vigil Neuroscience and Voyager Therapeutics.
Israel's Gamida Cell Survives By Selling To Lender
Having finally secured US approval for Omisirge, Gamida was hoping to bag a strategic partner for the cell therapy. A year on, no suitable partner has been identified and the firm is delisting from the NASDAQ and going private.